Literature DB >> 27233364

Multiple immune deviations predictive for IVF failure as possible markers for IVIG therapy.

Viktor P Chernyshov1, Boris V Dons'koi2, Iryna O Sudoma3, Yana O Goncharova4.   

Abstract

Recently we have shown that immune deviations (ID) may predict IVF failure. Benefit from IVIG therapy was observed in 115 women with repeated IVF failure according to proposed multiple ID that appeared unfavorable for implantation and live birth. Group of 123 women with repeated IVF failure without IVIG therapy was compared with former group. Immune phenotype and NK activity of peripheral blood lymphocytes were studied by flow cytometry. Potentially predictive for IVF failure ID included elevated expression of CD56, CD158a in T lymphocytes, decreased levels of CD4T lymphocytes, up-regulated expression of HLA DR in CD8+ T cells and NK cells, elevated number of NK cells and increased NK cytotoxicity, increased or decreased expression of CD158a and CD8 in NK cells. Three or more ID may predict implantation failure to a greater degree than one or two ID. In women receiving IVIG in subgroups with 0-1 and 2 ID, there was no increase in implantation rate (IR) and live birth rate (LBR) after IVIG in comparison with patients with the same number of ID but without IVIG correction. After IVIG therapy decreased IR and LBR were restored in women with three or more immune deviations. Multiple immune deviations indicate IVF patients who may benefit from IVIG therapy. IVIG seems to convert "unfavorable" immune phenotype to "favorable" one.
Copyright © 2016 European Federation of Immunological Societies. Published by Elsevier B.V. All rights reserved.

Entities:  

Keywords:  IVF failure; IVIG; Multiple immune deviations

Mesh:

Substances:

Year:  2016        PMID: 27233364     DOI: 10.1016/j.imlet.2015.12.010

Source DB:  PubMed          Journal:  Immunol Lett        ISSN: 0165-2478            Impact factor:   3.685


  1 in total

1.  Comparison of T and NK lymphocyte subsets between human endometrial tissue and peripheral blood.

Authors:  Viktor P Chernyshov; Boris V Dons'koi; Iryna O Sudoma; Yana O Goncharova
Journal:  Cent Eur J Immunol       Date:  2019-09-30       Impact factor: 2.085

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.